TAIPEI, Taiwan, April 10 /PRNewswire/ -- Rheumatoid arthritis (RA) is a systemic disease or an autoimmune disorder in which the body's defense system attacks the joints through the thin layer of cells called the synovium that lines and lubricates the joints. The most visible symptoms of RA are swollen joints and crippling stiffness, particularly of the hands and feet. It can cause fatigue, fever, loss of appetite and also impedes mobility and quality of life.
Frost & Sullivan, Research Analyst Sushma Rajan says, "Besides ankylosing spondylitis (AS) and system lupus erythmatosus (SLE), rheumatoid arthritis (RA) is one of the most common rheumatic diseases in Taiwan, with an incidence of 0.35 percent every year. The country registers a low prevalence rate for RA of 0.3 percent."
"About three times as many women are afflicted with RA than men. RA cases are higher in urban areas and the number of new cases diagnosed is seen to be increasing because of rising awareness of RA and earlier detection that allows patients to receive treatment in the early stages," she further explains.
RA is classified as a chronic disease under the Bureau of National Health Insurance (BNHI), Taiwan. This allows patients who are diagnosed with RA by their physicians to save significant medical costs as the co-payment of treatment and hospitalization is waived.
The diagnosis of RA is based on clinical examination of symptoms, patient history, as well as some blood tests. RA cannot be confirmed or excluded by any one test. The most common test is rheumatoid factor (RF). The other supporting tests are: anticyclic citrullinated peptide (Anti-CCP), erythrocyte sedimentation rate (ESR), and Xray.
"Recent work productivity studies have confirmed that better disease awareness and availability of treatment options have resulted in fewer patients ceasing to work and more patients reporting lower impact of their disease on work as well as family and social activities," she further elaborates.
Methotrexate (MTX), a DMARD (disease-modifying anti-rheumatic drugs) has been traditionally used to treat RA. It is also the most used form of treatment in rheumatoid arthritis, especially with generic forms available. Currently, combination therapies between DMARDs and NSAIDs (non-steroidal anti-inflammatory drugs) are commonly practiced.
DMARDs capture the majority of the RA therapeutics market owing to the availability of reimbursement for treatment with these drugs and their easy availability over the counter. DMARDs are expected to retain majority share in the forecast period as well.
According to Rajan, "Biologics are used in combination with DMARDs for moderate to severe RA patients. Some biologic drugs are currently reimbursed, if treated in government hospitals. Physicians opine that with more drugs brought into the hospital formularies, the usage of biologics would increase for treatment earlier in the disease."
Though there are new drugs available for treating RA, specialists in Taiwan are likely to continue using DMARDs as their first line therapy, as they have the most experience with this drug class, and it is seen as the most cost effective treatment option. Even though biologics are highly effective and recommended for treatment, they are likely to be the third line of treatment, due to their high cost. Physicians are willing to use biologics if they are listed in the hospital formulary and if they are affordable to their patients (current price range is seen to be out of reach of most patients). Physicians are of the opinion that more studies are required to make them feel confident in using biologics, but the cost of treatment is likely to restrain the high use of the drug class.
About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, enables clients to accelerate growth and achieve best in class positions in growth, innovation and leadership. The company's Growth Partnership Service provides the CEO and the CEO's Growth Team with disciplined research and best practice models to drive the generation, evaluation and implementation of powerful growth strategies. Frost & Sullivan leverages over 45 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from 31 offices on six continents. To join our Growth Partnership, please visit http://www.frost.com.
Contact: Emmie Kaur Corporate Communications -Healthcare, Asia Pacific DID: +603 6204 5913 Email: firstname.lastname@example.org Jasminder Kaur Corporate Communications -Healthcare, Asia Pacific DID: +65 6890 0937 Email: email@example.com
|SOURCE Frost & Sullivan|
Copyright©2009 PR Newswire.
All rights reserved